Advertisement
Advertisement
U.S. markets close in 2 hours 39 minutes
Advertisement
Advertisement
Advertisement
Advertisement

Iterum Therapeutics plc (ITRM)

NasdaqCM - NasdaqCM Real Time Price. Currency in USD
Add to watchlist
1.8600-0.0500 (-2.62%)
As of 01:08PM EDT. Market open.
Advertisement
Full screen
Trade prices are not sourced from all markets
Gain actionable insight from technical analysis on financial instruments, to help optimize your trading strategies
Chart Events
Bullishpattern detected
Price Crosses Moving Average

Price Crosses Moving Average

Previous Close1.9100
Open2.0200
Bid1.7800 x 900
Ask1.8700 x 1400
Day's Range1.8282 - 2.0200
52 Week Range1.5800 - 11.2500
Volume66,336
Avg. Volume281,764
Market Cap22.754M
Beta (5Y Monthly)1.40
PE Ratio (TTM)10.94
EPS (TTM)0.1700
Earnings DateAug 12, 2022
Forward Dividend & YieldN/A (N/A)
Ex-Dividend DateN/A
1y Target EstN/A
Fair Value is the appropriate price for the shares of a company, based on its earnings and growth rate also interpreted as when P/E Ratio = Growth Rate. Estimated return represents the projected annual return you might expect after purchasing shares in the company and holding them over the default time horizon of 5 years, based on the EPS growth rate that we have projected.
Fair Value
XX.XX
Overvalued

Subscribe to Yahoo Finance Plus to view Fair Value for ITRM

View details
Research that delivers an independent perspective, consistent methodology and actionable insight
Related Research
  • Iterum Therapeutics plc
    Analyst Report: Pfizer Inc.Pfizer is one of the world's largest pharmaceutical firms, with annual sales close to $50 billion (excluding COVID-19 vaccine sales). While it historically sold many types of healthcare products and chemicals, now, prescription drugs and vaccines account for the majority of sales. Top sellers include pneumococcal vaccine Prevnar 13, cancer drug Ibrance, cardiovascular treatment Eliquis, and immunology drug Xeljanz. Pfizer sells these products globally, with international sales representing close to 50% of its total sales. Within international sales, emerging markets are a major contributor.
    Rating
    Fair Value
    Economic Moat
    18 days agoMorningstar
View more
  • GlobeNewswire

    Iterum Therapeutics announces Issuance of Allowance for a U.S. Patent Covering Oral Sulopenem

    DUBLIN, Ireland and CHICAGO, Sept. 19, 2022 (GLOBE NEWSWIRE) -- Iterum Therapeutics plc (Nasdaq: ITRM) (the “Company” or “Iterum”), a clinical-stage pharmaceutical company focused on developing next generation oral and IV antibiotics to treat infections caused by multi-drug resistant pathogens in both community and hospital settings, today announced the United States Patent and Trademark Office has issued the Company a Notice of Allowance for U.S. patent application number 16/972,300 entitled “C

  • GlobeNewswire

    Iterum Therapeutics to Present at the H.C. Wainwright 24th Annual Global Investment Conference

    DUBLIN, Ireland and CHICAGO, Sept. 07, 2022 (GLOBE NEWSWIRE) -- Iterum Therapeutics plc (Nasdaq: ITRM) (the Company), a clinical-stage pharmaceutical company focused on developing next generation oral and IV antibiotics to treat infections caused by multi-drug resistant pathogens in both community and hospital settings, today announced that Corey Fishman, Chief Executive Officer, and Judy Matthews, Chief Financial Officer, will provide a company overview and business update at the H.C. Wainwrigh

  • GlobeNewswire

    Iterum Therapeutics Regains Compliance with Nasdaq Bid Price Rule

    DUBLIN, Ireland and CHICAGO, Sept. 01, 2022 (GLOBE NEWSWIRE) -- Iterum Therapeutics plc (Nasdaq: ITRM) (the “Company”), a clinical-stage pharmaceutical company focused on developing next generation oral and IV antibiotics to treat infections caused by multi-drug resistant pathogens in both community and hospital settings, today announced that it has received a letter from the Listing Qualifications Department of The Nasdaq Stock Market LLC (“Nasdaq”) notifying the Company that it has regained co

Advertisement
Advertisement